Krüppel-like factor 10 (KLF10) (KLF10)

Krüppel-like factor 10 (KLF10), also known as TGFB-inducible early growth response protein 1 (TIEG1), is a zinc-finger transcription factor that plays a pivotal role in mediating the effects of the transforming growth factor-beta (TGF-beta) signaling pathway [1]. It functions by binding to GC-rich sequences in the promoter regions of target genes, acting as either a repressor or an activator to regulate essential cellular processes such as proliferation, differentiation, and apoptosis [2]. KLF10 is critically involved in bone mineralization, where it promotes osteoblast differentiation, and in metabolic regulation, particularly glucose homeostasis in the liver [3]. In oncology, KLF10 is frequently characterized as a tumor suppressor, with its loss or downregulation linked to the progression of pancreatic, breast, and colon cancers [4]. It also plays a role in the regulation of the circadian clock, influencing the expression of core clock genes and metabolic outputs [3]. While there are currently no FDA-approved drugs that directly target KLF10 mRNA or protein, it is an area of active research for therapeutic intervention in metabolic diseases and cancer due to its central role in cellular signaling and gene expression [5]. Experimental approaches using siRNA or viral-mediated overexpression have demonstrated the potential of modulating KLF10 levels to alter disease phenotypes in preclinical models [2]. The complexity of its regulatory network and its broad tissue distribution present challenges for achieving specificity in drug development [5].

Other names

TIEG1TGFB-inducible early growth response protein 1EGR-alphaTIEGTGFB-inducible early growth response 1

Transcriptional regulation of target genes via binding to GC-rich promoter elements (5'-GGGGTG-3'), often acting as a downstream effector of TGF-beta signaling to repress or activate gene expression.